Drug Profile


Alternative Names: ALTU-135; LY-3031642; Sollpura; TheraCLEC™-Total; Trizytek™

Latest Information Update: 02 Jun 2017

Price : $50

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics
  • Developer Anthera Pharmaceuticals; Cystic Fibrosis Foundation Therapeutics
  • Class Amylases; Carboxylic ester hydrolases; Pancreatic enzymes; Peptide hydrolases
  • Mechanism of Action Amylase replacements; Lipase replacements; Peptide hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Exocrine pancreatic insufficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Exocrine pancreatic insufficiency

Most Recent Events

  • 28 Apr 2017 Anthera Pharmaceuticals initiates the phase III RESULT trial in Exocrine pancreatic insufficiency (In children, In adolescents, In adults) in USA (NCT03051490)
  • 29 Mar 2017 Efficacy and adverse events data from a long term observation of phase III SOLUTION trial in Exocrine pancreatic insufficiency released by Anthera Pharmaceuticals
  • 28 Feb 2017 Anthera Pharmaceuticals completes the phase III SIMPLICITY trial in Exocrine pancreatic insufficiency (In adolescents, In children, In infants, In adults) in USA (PO, Powder) (NCT02734810)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top